Tensive Controls Inc. Changes Name to Endevica Bio

“Our new name is the first of many milestones we expect to achieve this year,” said Russ Potterfield, Executive Chairman of Endevica Bio. “We expect our first therapeutic candidate, TCMCB07, to move through pre-clinical development to become the first-in-human drug candidate for cancer cachexia. With up to 40% of cancer patients dying from cachexia, we hope to address this major need and save millions of lives.”

Cachexia is also known as “Wasting Syndrome.” It is marked by weight loss, muscle loss, lack of appetite, fatigue and decreased strength. It can be a sign of cancer, as well as AIDS, heart failure, and/or chronic obstructive pulmonary disease (COPD). Cachexia is a serious clinical consequence estimated to be prevalent in approximately 50-80% of those with advanced malignant cancer and it is estimated to be the cause of death for up to 40% of cancer patients.

The new website for Endevica Bio can be found at endevicabio.com.

About Endevica Bio
Endevica Bio was formed in 2009 to create best-in-class peptide drug candidates with better safety and efficacy properties than other drugs in the same class. Endevica’s technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to perform with improved half-life, oral activity, and the ability to cross the blood-brain barrier. Endevica’s initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. The company expects to enter clinical development by Q1 2022. More information can be found at www.endevicabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005694/en/